-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In large observational studies, central antidopaminergic antipsychotics were associated with an increased risk of ischemic stroke, especially in the elderly and demented populations.
Return to normal levels after a month
.
Non-antipsychotic dopamine receptor antagonists, such as antidopaminergic antiemetics (ADAs), are also widely used in clinical practice, which act on peripheral blood D2 receptors
We conducted a case-control study to identify ischemic stroke risk associated with antidopaminergic antiemetic (ADA) use
The odds ratio for stroke was 3.
12 in patients receiving ADA compared with controls
Stroke risk highest on first day of ADA medication
Stroke risk highest on first day of ADA medication Highest stroke risk on first day of ADA medicationThe study found that the use of antidopaminergic antiemetics was associated with an increased risk of ischemic stroke, with metoprazine and metoclopramide having the highest risk
.
Use of antidopaminergic antiemetics was associated with an increased risk of ischemic stroke, with metoprazine and metoclopramide having the highest risk
.
Use of antidopaminergic antiemetics was associated with an increased risk of ischemic stroke, with metoprazine and metoclopramide having the highest risk
.
Original source:
Risk of first ischaemic stroke and use of antidopaminergic antiemetics: nationwide case-time-control study.
Leave a comment here